Latest News




A Very Big Thankyou from NeST & the Bristol Research team to 'Purespring Therapeutics' in London for kindly holding a bake sale and raising the AMAZING sum of £353.80 for Nephrotic Syndrome Research to mark 'World Kidney Day'!!! Wow!!

Friday, March 15, 2024

A Very Big Thankyou from NeST & the Bristol Research team to 'Purespring Therapeutics' in London for kindly holding a bake sale and raising the AMAZING sum of £353.80 for Nephrotic Syndrome Research to mark 'World Kidney Day'!!! Wow!!


Thankyou SO much to everyone who kindly baked cakes and everyone who bought cakes and gave very generous donations!! So kind of you all!!!
 
My very best wishes,
Wendy
 

For those of you who don't know Professor Moin Saleem and Dr, Gavin Welsh also oversee this lab in London two days a week. I gave a talk to the team if you remember last year.


Purespring Therapeutics is one of the first kidney gene therapy companies


The University of Bristol has secured a £45million deal to advance its groundbreaking gene therapy technology for chronic kidney diseases. The commitment, made by healthcare company Syncona Ltd to Bristol spin-out Purespring Therapeutics, aims to address a global unmet need for renal conditions in one of the largest single investments made to a new UK university biotech company.


The University of Bristol has secured a £45million deal to advance its groundbreaking gene therapy technology for chronic kidney diseases. The commitment, made by healthcare company Syncona Ltd to Bristol spin-out Purespring Therapeutics, aims to address a global unmet need for renal conditions in one of the largest single investments made to a new UK university biotech company.This investment marks a significant step forward in the innovation of long overdue new therapies for kidney diseases, which have historically been disproportionately expensive to treat.


Syncona’s £45 million investment to Purespring will be used to progress to the clinic gene therapy research pioneered by Professor Moin Saleem, Professor of Paediatric Renal Medicine at Bristol Medical School and Bristol Children’s Hospital, and Dr Gavin Welsh, Associate Professor of Renal Medicine. Professor Saleem’s work is the only study to date (as yet to be published) to have successfully demonstrated disease rescue in animal models using this technique for a kidney disorder called nephrotic syndrome.


Syncona’s £45 million investment to Purespring will be used to progress to the clinic gene therapy research pioneered by Professor Moin Saleem, Professor of Paediatric Renal Medicine at Bristol Medical School and Bristol Children’s Hospital, and Dr Gavin Welsh, Associate Professor of Renal Medicine. Professor Saleem’s work is the only study to date (as yet to be published) to have successfully demonstrated disease rescue in animal models using this technique for a kidney disorder called nephrotic syndrome.
 

Go back






Charity Web Design by Yeomedia Group